I am a neuro-oncologist specializing in more than 35 forms of nervous system cancers, with a research focus on glioblastoma. I also serve as an associate professor in the neurology department at the OSUCCC – James, and working alongside the talented cancer researchers and clinicians in the division of neuro-oncology is a truly rewarding experience. Additionally, I was named to the Castle Connolly list of “Regional Top Doctors” from 2015 to 2019.

At The James, we are advocates for our patients and continuously seek new ways to provide the most effective treatments possible. Treating nervous system cancers requires a management approach that includes not just one physician but a team of specialists, including neurosurgeons, radiation oncologists, pathologists, neuroimaging specialists and more. Our team works with innovative technologies to perform genetic and molecular analysis of brain tumors. The combination of our expertise and technological capabilities at The James means patients receive individualized treatment plans for their specific needs.

Research is also a major component of my career. As a member of the Translational Therapeutics Program at the OSUCCC – James, my research is focused on developing neuro-oncology clinical trials centering on newly diagnosed and recurrent glioblastoma, the most lethal form of brain cancer. I am particularly interested in designing clinical trials that feature targeted therapies for the treatments of patients with these tumors. I am also exploring cancer that has metastasized (spread) to the central nervous system in hopes of developing therapies based on correlative molecular studies. My work includes dozens of clinical research studies. Recently, I investigated a therapy for brain tumors utilizing components of the citrus, ginger and mushroom families that was published in the journal Tumor Biology. My work has also been published in several other top medical journals, including Anticancer Research and Neuro-Oncology. I have also presented my research to such organizations as the Brain Tumor Trials Collaborative, the International Symposium on Pediatric Neuro-Oncology and the American Society of Clinical Oncology.

Pierre Giglio, M.D., is now enrolling patients for the ReSPECT-GBM and ReSPECT-LM clinical trials.